Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing

Human Molecular Genetics

Volumn 24, Issue 8, 2015, Pages 2318-2329

  Kunstman, John W ^a   Christofer Juhlin, C ^a,c   Goh, Gerald ^a,b   Brown, Taylor C ^a   Stenman, Adam ^c   Healy, James M ^a   Rubinstein, Jill C ^a   Choi, Murim ^a,b   Kiss, Nimrod ^c   Nelson Williams, Carol ^a,b   Mane, Shrikant ^a   Rimm, David L ^a   Prasad, Manju L ^a   Höög, Anders ^c   Zedenius, Jan ^c   Larsson, Catharina ^c   Korah, Reju ^a   Lifton, Richard P ^a,b   Carling, Tobias ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; EIF1AX PRTOEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MLH3 PROTEIN; MSH5 PROTEIN; NF1 PROTEIN; NF2 PROTEIN; PROTEIN MLH1; PROTEIN MSH6; PROTEIN P53; PROTEIN RET; RAS PROTEIN; UNCLASSIFIED DRUG; USH2A PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CARCINOMA CELL LINE; CLINICAL ARTICLE; COHORT ANALYSIS; EXOME; FEMALE; GENE ONTOLOGY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERVENTION STUDY; INVESTIGATIVE PROCEDURES; MALE; MIDDLE AGED; MISMATCH REPAIR; MULTIGENE FAMILY; PHENOTYPE; PRIORITY JOURNAL; SOMATIC MUTATION; THYROID CARCINOMA; TUMOR GENE; VERY ELDERLY; GENETICS; MUTATION; THYROID TUMOR; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; EXOME; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84926511800     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu749     Document Type: Article

References (64)

1. Ragazzi, M., Ciarrocchi, A., Sancisi, V., Gandolfi, G., Bisagni, A. and Piana, S. (2014) Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int. J. Endocrinol., 2014, 790834.
2. Smallridge, R.C., Marlow, L.A. and Copland, J.A. (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer, 16, 17-44.
3. McIver, B., Hay, I.D., Giuffrida, D.F., Dvorak, C.E., Grant, C.S., Thompson, G.B., van Heerden, J.A. and Goellner, J.R. (2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery, 130, 1028-1034.
4. Smallridge, R.C., Ain, K.B., Asa, S.L., Bible, K.C., Brierley, J.D., Burman, K.D., Kebebew, E., Lee, N.Y., Nikiforov, Y.E., Rosenthal, M.S. et al. (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid, 22, 1104-1139.
5. Sugitani, I., Miyauchi, A., Sugino, K., Okamoto, T., Yoshida, A. and Suzuki, S. (2012) Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J. Surg., 36, 1247-1254.
6. Kebebew, E., Greenspan, F.S., Clark, O.H., Woeber, K.A. and McMillan, A. (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer, 103, 1330-1335.
7. Neff, R.L., Farrar, W.B., Kloos, R.T. and Burman, K.D. (2008) Anaplastic thyroid cancer. Endocrinol. Metab. Clin. North Am., 37, 525-538. xi.
8. Lam, K.Y., Lo, C.Y., Chan, K.W. and Wan, K.Y. (2000) Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann. Surg., 231, 329-338.
9. Venkatesh, Y.S., Ordonez, N.G., Schultz, P.N., Hickey, R.C., Goepfert, H. and Samaan, N.A. (1990) Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer, 66, 321-330.
10. Guerra, A., Di Crescenzo, V., Garzi, A., Cinelli, M., Carlomagno, C., Tonacchera, M., Zeppa, P. and Vitale, M. (2013) Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg., 13(Suppl 2), S44.
11. Nikiforov, Y.E. (2004) Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr. Pathol., 15, 319-327.
12. Santarpia, L., El-Naggar, A.K., Cote, G.J., Myers, J.N. and Sherman, S.I. (2008) Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab., 93, 278-284.
13. Garcia-Rostan, G., Tallini, G., Herrero, A., D'Aquila, T.G., Carcangiu, M.L. and Rimm, D.L. (1999) Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res., 59, 1811-1815.
14. Kurihara, T., Ikeda, S., Ishizaki, Y., Fujimori, M., Tokumoto, N., Hirata, Y., Ozaki, S., Okajima, M., Sugino, K. and Asahara, T. (2004) Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid, 14, 1020-1029.
15. Pita, J.M., Figueiredo, I.F., Moura, M.M., Leite, V. and Cavaco, B. M. (2014) Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J. Clin. Endocrinol. Metab., 99, E497-E507.
16. Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A.K. and Xing, M. (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab., 93, 3106-3116.
17. Sosa, J.A., Balkissoon, J., Lu, S.P., Langecker, P., Elisei, R., Jarzab, B., Bal, C.S., Marur, S., Gramza, A. and Ondrey, F. (2012) Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery, 152, 1078-1087.
18. Nixon, I.J., Shaha, A.R. and Tuttle, M.R. (2013) Targeted therapy in thyroid cancer. Curr. Opin. Otolaryngol. Head Neck Surg., 21, 130-134.
19. Jin, N., Jiang, T., Rosen, D.M., Nelkin, B.D. and Ball, D.W. (2009) Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab., 94, 4107-4112.
20. Wagle, N., Grabiner, B.C., Van Allen, E.M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., Gray, N., Barletta, J.A., Guo, Y., Swanson, S.J. et al. (2014) Response and acquired resistance to everolimus in anaplastic thyroid cancer. N. Engl. J. Med., 371, 1426-1433.
21. Rosove, M.H., Peddi, P.F. and Glaspy, J.A. (2013) BRAF V600E inhibition in anaplastic thyroid cancer. N. Engl. J. Med., 368, 684-685.
22. Bilguvar, K., Ozturk, A.K., Louvi, A., Kwan, K.Y., Choi, M., Tatli, B., Yalnizoglu, D., Tuysuz, B., Caglayan, A.O., Gokben, S. et al. (2010) Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations. Nature, 467, 207-210.
23. Choi, M., Scholl, U.I., Ji, W., Liu, T., Tikhonova, I.R., Zumbo, P., Nayir, A., Bakkaloglu, A., Ozen, S., Sanjad, S. et al. (2009) Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc. Natl Acad. Sci. USA, 106, 19096-19101.
24. Cromer, M.K., Starker, L.F., Choi, M., Udelsman, R., Nelson-Williams, C., Lifton, R.P. and Carling, T. (2012) Identification of somatic mutations in parathyroid tumors using wholeexome sequencing. J. Clin. Endocrinol. Metab., 97, E1774-E1781.
25. Zhao, S., Choi, M., Overton, J.D., Bellone, S., Roque, D.M., Cocco, E., Guzzo, F., English, D.P., Varughese, J., Gasparrini, S. et al. (2013) Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl Acad. Sci. USA, 110, 2916-2921.
26. Krauthammer, M., Kong, Y., Ha, B.H., Evans, P., Bacchiocchi, A., McCusker, J.P., Cheng, E., Davis, M.J., Goh, G., Choi, M. et al. (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet., 44, 1006-1014.
27. Haimovich, A.D. (2011) Methods, challenges, and promise of next-generation sequencing in cancer biology. Yale J. Biol. Med., 84, 439-446.
28. Vater, I., Montesinos-Rongen, M., Schlesner, M., Haake, A., Purschke, F., Sprute, R., Mettenmeyer, N., Nazzal, I., Nagel, I., Gutwein, J. et al. (2014) The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia, doi: 10.1038/leu. 2014.264.
29. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, Jr. L.A. and Kinzler, K.W. (2013) Cancer genome landscapes. Science, 339, 1546-1558.
30. Liu, D., Yang, C., Bojdani, E., Murugan, A.K. and Xing, M. (2013) Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J. Natl Cancer Inst., 105, 1617-1627.
31. Kelly, L.M., Barila, G., Liu, P., Evdokimova, V.N., Trivedi, S., Panebianco, F., Gandhi, M., Carty, S.E., Hodak, S.P., Luo, J. et al. (2014) Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc. Natl Acad. Sci. USA, 111, 4233-4238.
32. Perot, G., Soubeyran, I., Ribeiro, A., Bonhomme, B., Savagner, F., Boutet-Bouzamondo, N., Hostein, I., Bonichon, F., Godbert, Y. and Chibon, F. (2014) Identification of a recurrent STRN/ ALK fusion in thyroid carcinomas. PLoS One, 9, e87170.
33. Agrawal, N., Akbani, R., Aksoy, B.A., Ally, A., Arachchi, H., Asa, S.L., Auman, J.T., Balasundaram, M., Balu, S., Baylin, S.B. et al. (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell, 159, 676-690.
34. Schwarz, J.M., Cooper, D.N., Schuelke, M. and Seelow, D. (2014) MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods, 11, 361-362.
35. Lee, J.J., Foukakis, T., Hashemi, J., Grimelius, L., Heldin, N.E., Wallin, G., Rudduck, C., Lui, W.O., Hoog, A. and Larsson, C. (2007) Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. Thyroid, 17, 289-301.
36. Garcia-Rostan, G., Zhao, H., Camp, R.L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M.L., Costa, J. and Tallini, G. (2003) ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol., 21, 3226-3235.
37. Milosevic, Z., Pesic, M., Stankovic, T., Dinic, J., Milovanovic, Z., Stojsic, J., Dzodic, R., Tanic, N. and Bankovic, J. (2014) Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl. Res., 164, 411-423.
38. Ricarte-Filho, J.C., Ryder, M., Chitale, D.A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J.A., Tuttle, R.M. et al. (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res., 69, 4885-4893.
39. Xing, M. (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer, 13, 184-199.
40. McFadden, D.G., Vernon, A., Santiago, P.M., Martinez-McFaline, R., Bhutkar, A., Crowley, D.M., McMahon, M., Sadow, P. M. and Jacks, T. (2014) p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc. Natl Acad. Sci. USA, 111, E1600-E1609.
41. Charles, R.P., Silva, J., Iezza, G., Phillips, W.A. and McMahon, M. (2014) Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol. Cancer Res., 12, 979-986.
42. Martin, M., Masshofer, L., Temming, P., Rahmann, S., Metz, C., Bornfeld, N., van de Nes, J., Klein-Hitpass, L., Hinnebusch, A. G., Horsthemke, B. et al. (2013) Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet., 45, 933-936.
43. Ewens, K.G., Kanetsky, P.A., Richards-Yutz, J., Purrazzella, J., Shields, C.L., Ganguly, T. and Ganguly, A. (2014) Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Invest. Ophthalmol. Vis. Sci., 55, 5160-5167.
44. Field, M.G. and Harbour, J.W. (2014) Recent developments in prognostic and predictive testing in uveal melanoma. Curr. Opin. Ophthalmol., 25, 234-239.
45. Yu, C., Luo, C., Qu, B., Khudhair, N., Gu, X., Zang, Y., Wang, C., Zhang, N., Li, Q. and Gao, X. (2014) Molecular network including eIF1AX, RPS7, and 14-3-3gamma regulates protein translation and cell proliferation in bovine mammary epithelial cells. Arch. Biochem. Biophys., 564, 142-155.
46. Hardt, M., Chantaravisoot, N. and Tamanoi, F. (2011) Activating mutations of TOR (target of rapamycin). Genes Cells, 16, 141-151.
47. Roskoski, R., Jr. (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res., 79, 34-74.
48. Ross, J.S., Wang, K., Gay, L.M., Al-Rohil, R.N., Nazeer, T., Sheehan, C.E., Jennings, T.A., Otto, G.A., Donahue, A., He, J. et al. (2014) A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin. Cancer Res., 20, 68-75.
49. Kim, N., Hong, Y., Kwon, D. and Yoon, S. (2013) Somatic mutaome profile in human cancer tissues. Genomics Inform., 11, 239-244.
50. Eudy, J.D., Weston, M.D., Yao, S., Hoover, D.M., Rehm, H.L., Ma-Edmonds, M., Yan, D., Ahmad, I., Cheng, J.J., Ayuso, C. et al. (1998) Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science, 280, 1753-1757.
51. Yoshida, R., Miyashita, K., Inoue, M., Shimamoto, A., Yan, Z., Egashira, A., Oki, E., Kakeji, Y., Oda, S. and Maehara, Y. (2011) Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. Eur. J. Hum. Genet., 19, 320-325.
52. Loeb, L.A. (2011) Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer, 11, 450-457.
53. Birkbak, N.J., Kochupurakkal, B., Izarzugaza, J.M., Eklund, A. C., Li, Y., Liu, J., Szallasi, Z., Matulonis, U.A., Richardson, A. L., Iglehart, J.D. et al. (2013) Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One, 8, e80023.
54. Shcherbakova, P.V. and Kunkel, T.A. (1999) Mutator phenotypes conferred by MLH1 overexpression and by heterozygosity for mlh1 mutations. Mol. Cell. Biol., 19, 3177-3183.
55. Stulp, R.P., Herkert, J.C., Karrenbeld, A., Mol, B., Vos, Y.J. and Sijmons, R.H. (2008) Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum. Hered. Cancer Clin. Pract., 6, 15-21.
56. Fagin, J.A., Matsuo, K., Karmakar, A., Chen, D.L., Tang, S.H. and Koeffler, H.P. (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest., 91, 179-184.
57. Garcia-Rostan, G., Camp, R.L., Herrero, A., Carcangiu, M.L., Rimm, D.L. and Tallini, G. (2001) Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol., 158, 987-996.
58. Paes, J.E. and Ringel, M.D. (2008) Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol. Metab. Clin. North Am., 37, 375-387. viii-ix.
59. Cordenonsi, M., Montagner, M., Adorno, M., Zacchigna, L., Martello, G., Mamidi, A., Soligo, S., Dupont, S. and Piccolo, S. (2007) Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science, 315, 840-843.
60. Guo, X. and Wang, X.F. (2009) Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res., 19, 71-88.
61. Holley, T., Lenkiewicz, E., Evers, L., Tembe, W., Ruiz, C., Gsponer, J.R., Rentsch, C.A., Bubendorf, L., Stapleton, M., Amorese, D. et al. (2012) Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS One, 7, e50586.
62. Menon, R., Deng, M., Boehm, D., Braun, M., Fend, F., Boehm, D., Biskup, S. and Perner, S. (2012) Exome enrichment and SOLiD sequencing of formalin fixed paraffin embedded (FFPE) prostate cancer tissue. Int. J. Mol. Sci., 13, 8933-8942.
63. Schweppe, R.E., Klopper, J.P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J.A., Fagin, J.A., Marlow, L.A., Copland, J.A., Smallridge, R.C. et al. (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals crosscontamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab., 93, 4331-4341.
64. Wennerberg, E., Pfefferle, A., Ekblad, L., Yoshimoto, Y., Kremer, V., Kaminskyy, V.O., Juhlin, C.C., Hoog, A., Bodin, I., Svjatoha, V. et al. (2014) Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells. Clin. Cancer Res., 20, 5733-5744.